Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nadezda I. Sultanbaeva"'
Autor:
Alexander V. Sultanbaev, Shamil I. Musin, Konstantin V. Menshikov, Nadezda I. Sultanbaeva, Irina A. Tuzankina, Danila O. Lipatov, Irina A. Menshikova, Mikhail V. Sultanbaev, Dmitry A. Kudlay, Andrey P. Prodeus
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 132-138 (2024)
Background. In oncology, of particular interest is the study of the T-cell receptor excision circles (TREC) and the κ-deletion B-cell receptor excision circles (KREC), which are extrachromosomal DNA structures. In many malignancies, the effectivenes
Externí odkaz:
https://doaj.org/article/5ed0020daa5b4dd1849ab3aab2568c61
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva, Radmir R. Rakhimov, Danila O. Lipatov, Irina A. Menshikova, Adel A. Izmailov, Elena E. Lipatova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 65-72 (2024)
Background. The combination of alpelisib with fulvestrant is the optimal targeted endocrine therapy for patients with hormone-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with mutations in the PIK3CA gene. This regimen has been
Externí odkaz:
https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Irina R. Gilyazova, Ainur F. Nasretdinov, Shamil I. Musin, Nadezda I. Sultanbaeva, Konstantin V. Menshikov
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 48-55 (2024)
Carriers of germinal mutations are at high risk of developing malignant neoplasms, characterized by an early age of manifestation, an aggressive course, and a high risk of recurrence. The wide introduction of medical genetic testing in the target pop
Externí odkaz:
https://doaj.org/article/e66b61080f3f4d0e823f5fd21c6b01f5
Autor:
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 340-344 (2022)
Knowledge of the molecular characteristics of the progression of non-small cell lung tumors currently provides the patient with the best treatment options. One of the most well-known and studied genetic abnormalities is a mutation in the EGFR gene, w
Externí odkaz:
https://doaj.org/article/ebd429d188994256bcbd1e16341b2425
Autor:
Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Shamil I. Musin, Irina A. Menshikova, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 112-115 (2021)
Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with
Externí odkaz:
https://doaj.org/article/84b8fb205d4b4a0d9e375fb79bab01f4
Autor:
Alexander V. Sultanbaev, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Alfiya A. Fatikhova, Adel A. Izmailov, Oleg N. Lipatov, Rustam T. Ayupov, Nadezda I. Sultanbaeva, Irina A. Menshikova, Grigorii A. Serebrennikov
Publikováno v:
Journal of Modern Oncology. 24:221-225
Background. PARP inhibitor olaparib shows encouraging results in the treatment of patients with BRCA-associated tumors. The detection of new tumors associated with abnormalities of the BRCA gene, also can lead to the expansion of PARP inhibitors appl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d910f4192ada16c84cb5e69609141b3
https://doi.org/10.26442/18151434.2022.2.201550
https://doi.org/10.26442/18151434.2022.2.201550